Reig Jofre increases sales by 7%, EBITDA by 12,5% and net profit by 7,5% at the end of June
The company reached €90.1 M in sales (+ 7%), driven mainly by the excellent growth of its nutritional supplements line in France (+ 42%) and the antibiotic and injectable products line (+ 11%).
EBITDA stood at €7.6 M (+ 12.5%) and net result at €2.96 M, with 7.5% growth due mainly to the impact of higher amortizations.
Operating expenses increased 13% with respect to previous year, due mainly to the increase in marketing expenses of the nutritional supplements division by Forté Pharma's launch campaigns and higher R&D expenses.
Total investment in the first half amounted to €8 M. The investment in productive assets reached €5.6 M derived from the completion of the Toledo plant expansion; the start of the new facilities construction at the Barcelona plant; and the adaptation to the European Directive EU 2011/62 for the prevention of counterfeit medicines. Investment in R&D stood at additional €2.4 M (+ 11%).
The company's liquidity reduced due to the increase in investments and non-current assets. Net debt stood at €20.2 M from €18.3 M at the end of 2017.
A scrip dividend was distributed, which represented the issuance of 896,889 new shares, 1.4% outstanding shares more. Free float will increase more than 8% up to 15.8%.
Attachments
Original document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 26 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 July 2018 07:40:06 UTC
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
